{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:17:43Z","timestamp":1761743863048},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of resistant hypertension (<jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content>) is not well established. Furthermore, diuretics, angiotensin\u2010converting enzyme inhibitors or angiotensin\u2010receptor blockers, and calcium channel blockers are largely used as the first 3\u2010drug combinations for treating <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content>. However, the fourth drug to be added to the triple regimen is still controversial and guided by empirical choices. We sought (1) to determine the prevalence of <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content> in patients with stage <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> hypertension; (2) to compare the effects of spironolactone vs clonidine, when added to the triple regimen; and (3) to evaluate the role of measuring sympathetic and renin\u2010angiotensin\u2010aldosterone activities in predicting blood pressure response to spironolactone or clonidine. The Resistant Hypertension Optimal Treatment (<jats:styled-content style=\"fixed-case\">ReHOT<\/jats:styled-content>) study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> <jats:styled-content style=\"fixed-case\">NCT01643434<\/jats:styled-content>) is a prospective, multicenter, randomized trial comprising 26 sites in Brazil. In step 1, 2000 patients will be treated according to hypertension guidelines for 12 weeks, to detect the prevalence of <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content>. Medical therapy adherence will be checked by pill count monitoring. In step 2, patients with confirmed <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content> will be randomized to an open label 3\u2010month treatment with spironolactone (titrating dose, 12.5\u201350 mg once daily) or clonidine (titrating dose, 0.1\u20130.3 mg twice daily). The primary endpoint is the effective control of blood pressure after a 12\u2010week randomized period of treatment. The <jats:styled-content style=\"fixed-case\">ReHOT<\/jats:styled-content> study will disseminate results about the prevalence of <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content> in stage <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> hypertension and the comparison of spironolactone vs clonidine for blood pressure control in patients with <jats:styled-content style=\"fixed-case\">ReHy<\/jats:styled-content> under 3\u2010drug standard regimen.<\/jats:p>","DOI":"10.1002\/clc.22228","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T20:53:15Z","timestamp":1386795195000},"page":"1-6","source":"Crossref","is-referenced-by-count":17,"title":["Resistant Hypertension Optimal Treatment Trial: A Randomized Controlled Trial"],"prefix":"10.1002","volume":"37","author":[{"name":"The ReHOT Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550160092044"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.788497"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012065"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.179788"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013953.41667.09"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.100701"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.189141"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.097345"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030189"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.170308"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.168948"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.068064"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02083-1"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.123455"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000259805.18468.8c"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-004-0071-z"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-007-0054-y"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000016176.16042.2F"},{"issue":"1","key":"e_1_2_5_22_1","first-page":"47","article-title":"Treatment of diuretic\u2010resistant arterial hypertension \u2010 crossed comparative study of verapamil and clonidine [in Portuguese]","volume":"36","author":"Maciel RM","year":"1981","journal-title":"Arq Bras Cardiol"},{"key":"e_1_2_5_23_1","first-page":"863","article-title":"Evaluation and management of the patient with difficult\u2010to\u2010control or resistant hypertension","volume":"79","author":"Viera AJ","year":"2009","journal-title":"Am Fam Physician."},{"key":"e_1_2_5_24_1","first-page":"e24","volume":"89","year":"2007","journal-title":"Arq Bras Cardiol"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76a.09030"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67573-3"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03290280031022"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(77)90108-4"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-7-199910050-00002"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80260-4"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.12.017"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283551e98"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.169961"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283567338"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:28:31Z","timestamp":1696318111000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/clc.22228"],"URL":"https:\/\/doi.org\/10.1002\/clc.22228","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}